Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade

Acta Biochimica et Biophysica Sinica

Volumn 41, Issue 12, 2009, Pages 980-990

  Zheng, Jin ^a   Jing, Weiqing ^b   Orentas, Rimas J ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Costimulatory molecule; Neuroblastoma; SEREX; Treg blockade

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR ANTIGEN; YBX1 PROTEIN, HUMAN;

ANIMAL; ARTICLE; BLOOD; CELLULAR IMMUNITY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NEUROBLASTOMA; PATHOLOGY; REGULATORY T LYMPHOCYTE; TUMOR CELL LINE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; IMMUNITY, CELLULAR; MICE; NEUROBLASTOMA; NUCLEAR PROTEINS; T-LYMPHOCYTES, REGULATORY; VACCINATION;

MUS;

EID: 71949097625     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmp092     Document Type: Article

References (45)

1. Brodeur GM and Castleberry RP. Neuroblastoma. In: Pizzo PA and Poplack DG eds, Principles and Practice of Pediatric Oncology, 3rd edn. 1997, 761.
2. Izbicki T, Mazur J and Izbicka E. Epidemiology and etiology of neuroblastoma: A n overview. Anticancer Res 2003, 23: 755-760.
3. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK and Swift P et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999, 341: 1165-1173.
4. Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS and Blazar BR. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother Emphasis Tumor Immunol 1994, 15: 81-90.
5. Hock RA, Reynolds BD, Tucker-McClung CL and Kwok WW. Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors. J Immunother Emphasis Tumor Immunol 1995, 17: 12-18.
6. Katsanis E, Bausero MA, Xu H, Orchard PJ, Xu Z, McIvor RS and Brian AA et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunol Immunother 1994, 38: 135-141.
7. Johnson BD, Yan X, Schauer DW and Orentas RJ. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell Immunol 2003, 222: 15-26.
8. Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X and Orentas RJ. Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J Immunother 2005, 28: 449-460.
9. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z and Smith SC et al. Local and systemic effects of an allogeneic tumor cell vaccine combining human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003, 101: 1718-1726.
10. Johnson BD, Jing W and Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 2007, 30: 203-214.
11. Dudley ME, Wunderlich J, Robbins PF, Yang JC, Hwu P, Schwartsentruber DJ and Topalian S et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298: 850-854.
12. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M and Huniyasu Y et al. Immunologic tolerance maintained by CD25+CD4+ regualtory T cells: T heir common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182: 18-23.
13. Golgher D, Jones E, Powrie F, Elliot T and Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002, 32: 3267-3275.
14. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R and Stenner F et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995, 92: 11810-11813.
15. Sahin U, Tureci O and Pfreundshuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997, 9: 709-716.
16. Chen YT, Scanlan MJ, Obata Y, Old LJ and Rosenberg SA. Identification of Human Tumor Antigens by Serological Expression Cloning. Prinicples and Practice of Biological Therapy of Cancer. Vol.3. Philadelphia: Lippincott Williams & Williams, 2000, 557.
17. Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD and Orentas RJ. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. BMC Immunol 2007, 8: 4.
18. Belgrader P, Dey R and Berezney R. Molecular cloning of matrin 3. A 125-kilodalton protein of the nuclear matrix contains an extensive acidic domain. J Biol Chem 1991, 266: 9893-9899. (Pubitemid 21906738)
19. Vieira HL, Haouzi D, El Hamel C, Jacotot E, Belzacq AS, Brenner C and Kroemer G. Permeabilization of the mitochondrial inner membrane during apoptosis: Impact of the adenine nucleotide translocator. Cell Death Differ 2000, 7: 1146-1154.
20. Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T and Inoue N et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007, 13: 1193-1202.
21. Chen J, Kaul S and Simons SS, Jr. Structure/activity elements of the multifunctional protein, GMEB-1. Characterization of domains relevant for the modulation of glucocorticoid receptor transactivation properties. J Biol Chem 2002, 277: 22053-22062.
22. Conibear E and Stevens TH. Vps52p, Vps53p, and Vps54p form a novel multisubunit complex required for protein sorting at the yeast late Golgi. Mol Biol Cell 2000, 11: 305-323.
23. Li H, Degenhardt B, Tobin D, Yao ZX, Tasken K and Papadopoulos V. Identification, localization, and function in steroidogenesis of PAP7: A peripheral-type benzodiazepine receptor- and PKA (RIa)-associated protein. Mol Endocrinol 2001, 15: 2211-2228.
24. Gui JF, Lane WS and Fu XD. A serine kinase regulates intracellular localization of splicing factors in the cell cycle. Nature 1994, 369: 678-682.
25. Dahl HH, Brown GK, Brown RM, Hansen LL, Kerr DS, Wexler ID and Patel MS et al. Mutations and polymorphisms in the pyruvate dehydrogenase E1 alpha gene. Hum Mutat 1993, 1: 97-102.
26. Matsumoto-Taniura N, Pirollet F, Monroe R, Gerace L and Westendorf JM. Identification of novel M phase phosphoproteins by expression cloning. Mol Biol Cell 1996, 7: 1455-1469.
27. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H and Schmitt M. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003, 106: 224-231.
28. Resto VA, Caballero OL, Buta MR, Westra WH, Wu L, Westendorf JM and Jen J et al. A putative oncogenic role for MPP11 in head and neck squamous cell cancer. Cancer Res 2000, 60: 5529-5535.
29. Kroger S and Schroder JE. Agrin in the developing CNS: new roles for a synapse organizer. News Physiol Sci 2002, 17: 207-212.
30. Guay D, Evoy AA, Paquet E, Garand C, Bachvarova M, Bachvarov D and Lebel M. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Int J Biochem Cell Biol 2008, 40: 2492-2507.
31. Mentlein R. Proline residues in the maturation and degradation of peptide hormones and neuropeptides. FEBS Lett 1988, 234: 251-256.
32. Bardoni B, Willemsen R, Weiler IJ, Schenck A, Severijnen LA, Hindelang C and Lalli E et al. NUFIP1 (nuclear FMRP interacting protein 1) is a nucleocytoplasmic shuttling protein associated with active synaptoneurosomes. Exp Cell Res 2003, 289: 95-107.
33. Wreggett KA, Hill F, James PS, Hutchings A, Butcher GW and Singh PB. A mammalian homologue of Drosophila heterochromatin protein 1 (HP1) is a component of constitutive heterochromatin. Cytogenet Cell Genet 1994, 66: 99-103.
34. Sharma GG, Hwang KK, Pandita RK, Gupta A, Dhar S, Parenteau J and Agarwal M et al. Human heterochromatin protein 1 isoforms HP1(Hsa) and HP1(Hsb) interfere with hTERT-telomere interactions and correlate with changes in cell growth and response to ionizing radiation. Mol Cell Biol 2003, 23: 8363-8376.
35. Stoffler D, Fahrenkrog B and Aebi U. The nuclear pore complex: from molecular architecture to functional dynamics. Curr Opin Cell Biol 1999, 11: 391-401.
36. Hood JK and Silver PA. Diverse nuclear transport pathways regulate cell proliferation and oncogenesis. Biochim Biophys Acta 2000, 1471: 31-41.
37. Nagel RJ, Lancaster AM and Zahler AM. Specific binding of an exonic splicing enhancer by the pre-mRNA splicing factor SRp55. RNA 1998, 4: 11-23.
38. Simonsen A, Lippé R, Christoforidis S, Gaullier JM, Brech A, Callaghan J and Toh BH et al. EEA1 links PI3K function to Rab5 regulation of endosome fusion. Nature 1998, 394: 494-498.
39. Sun L, Youn HD, Loh C, Stolow M, He W and Liu JO. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity 1998, 8: 703-711.
40. Imataka H, Olsen HS and Sonenberg N. A new translational regulator with homology to eukaryotic translation initiation factor 4G. EMBO J 1997, 16: 817-825.
41. Funke B, Zuleger B, Benavente R, Schuster T, Goller M, Stévenin J and Horak I. The mouse poly(C)-binding protein exists in multiple isoforms and interacts with several RNA-binding proteins. Nucleic Acids Res 1996, 24: 3821-3828.
42. Lage H, Surowiak P and Holm PS. YB-1 as a potential target in cancer therapy. Pathologe 2008, 29: 187-190.
43. Fujii T, Yokoyama G, Takahashi H, Namoto R, Nakagawa S, Toh U and Kage M et al. Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Breast Cancer 2008, 15: 73-78.
44. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP and Kumar SD et al. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol 2009, 22: 282-290.
45. Bieler A, Mantwill K, Holzmu ller R, Ju rchott K, Kaszubiak A, Stark S and Glockzin G et al. Impact of radiation therapy on the oncolytic adenovirus dl520: Implications on the treatment of glioblastoma. Radiother Oncol 2008, 86: 419-427.